Interpretation of SL-LPA: Predicting Drug Resistance

Zone developed/ not developed (failed) in Wild Type (WT) and Mutation (MUT) probes are used to predict drugs resistance in Second Line - Line Probe Assay (SL - LPA).

For Fluoroquinolones (FLQ)

Tables 1 and 2 show mutations in gyrA, gyrB genes and corresponding WT, MUT and responsible codons and mutations:

• gyrA WT1-3: gyrA wild type probes; gyrA MUT1-2, 3A-3D: gyrA mutation probes
• gyrB WT: gyrB wild type probes; gyrB MUT1-2: gyrB mutation probes

Table 1: Mutations in gyrA gene and corresponding wild type and mutation band; Source: GenoType MTBDRsl Ver 2.0 Kit, Instructions for Use.

Table 2: Mutations in gyrB gene and corresponding wild type and mutation band; Source: GenoType MTBDRsl Ver 2.0 Kit, Instructions for Use.

For Second Line Injectable Drugs - Kanamycin (KAN), Amikacin (AMK), Capreomycin (CAP)

Tables 3 and Table 4 show mutations in rrs gene and eis gene respectively and corresponding WT and MUT bands:

• rrs WT 1-2: rrs wild type probe; rrs MUT 1-2: rrs mutation probe
• eis WT 1-3: eis wild type probe; eis MUT 1: eis mutation probe

Table 3: Mutations in rrs gene and corresponding WT, MUT bands and responsible codons and mutations; Source: GenoType MTBDRsl Ver 2.0 Kit, Instructions for Use.

Table 4: Mutations in eis gene and corresponding WT, MUT bands and responsible codons and mutations; Source: GenoType MTBDRsl Ver 2.0 Kit, Instructions for Use.

Resources

• GenoType MTBDRsl Ver 2.0 Kit, Instructions for Use.
• Line Probe Assays for Drug-resistant Tuberculosis Detection, GLI.

Kindly provide your valuable feedback on the page to the link provided HERE